What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To evaluate sustained minimal residual disease (MRD) negativity in patients treated with belantamab mafodotin and dexamethasone in the DREAMM-7 trial.

December 8, 2025BloodOpen Access

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

View Full Paper

Ask AI

Bookmark

Authors

PRPaweł Robak PHPhoebe Joy Ho RHRoman Hájek

Discussion

Member takes

Overview

Phase 3 trial reveals greater MRD negativity and sustained responses in relapsed/refractory myeloma treated with dexamethasone and belantamab.

Key Points

To evaluate sustained minimal residual disease (MRD) negativity in patients treated with belantamab mafodotin and dexamethasone in the DREAMM-7 trial.
Phase 3 randomized trial comparing BVd and DVd in patients with relapsed/refractory multiple myeloma.
Primary endpoint: progression-free survival (PFS); secondary endpoints include MRD negativity and overall survival (OS).
MRD negativity assessed through next-generation sequencing.
CR-based MRD negativity rates were 70% for BVd vs 59% for DVd at the 10−5 sensitivity threshold.
Sustained MRD negativity for ≥12 months observed in 57% of BVd patients vs 42% of DVd patients.
Median time to first CR-based MRD negativity was shorter for BVd arm (11.14 months) compared to DVd (17.02 months).

Cite This Study

Robak et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df3c https://doi.org/10.1182/blood-2025-2265

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

View Full Paper

Ask AI

Bookmark

Authors

PRPaweł Robak PHPhoebe Joy Ho RHRoman Hájek

Discussion

Member takes

Overview

Phase 3 trial reveals greater MRD negativity and sustained responses in relapsed/refractory myeloma treated with dexamethasone and belantamab.

Key Points

To evaluate sustained minimal residual disease (MRD) negativity in patients treated with belantamab mafodotin and dexamethasone in the DREAMM-7 trial.
Phase 3 randomized trial comparing BVd and DVd in patients with relapsed/refractory multiple myeloma.
Primary endpoint: progression-free survival (PFS); secondary endpoints include MRD negativity and overall survival (OS).
MRD negativity assessed through next-generation sequencing.
CR-based MRD negativity rates were 70% for BVd vs 59% for DVd at the 10−5 sensitivity threshold.
Sustained MRD negativity for ≥12 months observed in 57% of BVd patients vs 42% of DVd patients.
Median time to first CR-based MRD negativity was shorter for BVd arm (11.14 months) compared to DVd (17.02 months).

Cite This Study

Robak et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df3c https://doi.org/10.1182/blood-2025-2265

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark